We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PCRX market cap is 781.71M. The company's latest EPS is USD 0.9086 and P/E is 18.93.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 160.57M | 183.52M | 170.92M | 176.51M | 171.82M |
| Operating Income | 17.72M | 33.17M | 13.21M | 28.24M | -139.53M |
| Net Income | 10.86M | 24.87M | 8.98M | 18.89M | -143.47M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 421.03M | 429.65M | 541.53M | 666.82M | 678.4M |
| Operating Income | 10.48M | 46.35M | 89.92M | 60.02M | 87.68M |
| Net Income | -11.02M | 145.52M | 41.98M | 15.91M | 41.96M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.53B | 1.57B | 1.58B | 1.65B | 1.52B |
| Total Liabilities | 702.91M | 704.26M | 691.16M | 767.54M | 772.11M |
| Total Equity | 831.55M | 870.13M | 892.16M | 879.28M | 749.58M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 831.07M | 1.27B | 2.08B | 1.68B | 1.57B |
| Total Liabilities | 476.12M | 654.83M | 1.34B | 906.19M | 704.26M |
| Total Equity | 354.94M | 619.69M | 730.41M | 775.01M | 870.13M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 107.07M | 154.65M | 49.1M | 102.34M | 156.26M |
| Investing | 69.17M | 77.54M | -15.53M | -30.75M | -82.91M |
| Financing | -181.25M | -183.03M | -2.82M | 22.16M | 19.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 70.52M | 77.03M | 125.72M | 145.27M | 154.65M |
| Investing | -128.49M | -277.61M | -20.79M | -225.19M | 77.54M |
| Financing | 3.67M | 222.3M | 380.69M | -401.53M | -183.03M |
| Market Cap | 781.71M |
| Price to Earnings Ratio | 18.93 |
| Price to Sales Ratio | 1.17 |
| Price to Cash Ratio | 5.18 |
| Price to Book Ratio | 0.91 |
| Dividend Yield | - |
| Shares Outstanding | 46.17M |
| Average Volume (1 week) | 460.01k |
| Average Volume (1 Month) | 578.29k |
| 52 Week Change | -39.30% |
| 52 Week High | 35.95 |
| 52 Week Low | 11.26 |
| Spread (Intraday) | 0.07 (0.41%) |
| Company Name | Pacira BioSciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.pacira.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
